MedWatch

Ambu CEO on stream of launches: "Won't be easy, but we're building an ecosystem"

In the next three years, Ambu expects to launch four times as many products as during its prior strategy period, and the CEO sees clear advantages to scaling the firm at this speed. At the same time, the company needs to succeed with the ecosystem of products which the CEO plans to establish at hospitals worldwide.

Ambu CEO Juan Jose Gonzalez | Photo: Ambu/PR

Ambu is pushing the pedal to the metal to establish itself on the single-use endoscope market.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs